Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort

Hélène Meillat1*, Vincent Niziers1, Christophe Zemmour2, Jacques Ewald1, Jean-Philippe Ratone3, Slimane Dermeche4 and Jérôme Guiramand1

Abstract

Background and purpose: To report the postoperative and oncological outcomes of transhiatal esophagectomy for locally advanced cancer of the gastroesophageal junction.

Methods: Medical records of 120 consecutive patients who underwent transhiatal esophagectomy for locally advanced cancer of the gastroesophageal junction with curative intent after neoadjuvant treatment between February 2006 and December 2018 at our center were reviewed.

Results: All patients received either chemotherapy (46.7%) or chemoradiation (53.3%). The 90-day mortality and overall morbidity rates were 0.8% and 56.7%, respectively. Respiratory complications were the most common (30.8%). Anastomotic leakage occurred in 19 patients (15.8%), who were treated by local wound care (n = 13) or surgical drainage (n = 6). Recurrent laryngeal nerve injury occurred in 12 patients (9.9%). The median length of hospital stay was 15.5 days. The rate of R0 resection was 95.8%, and the median number of nodes removed was 17.5. Over a median follow-up of 77 months, the rate of recurrence was 40.8%, and the overall survival rates at 1, 3, and 5 years were 91%, 75%, and 65%, respectively. The median survival time was not reached. In multivariate analysis, disease stage was the only independent significant prognostic factor.

Conclusions: Transhiatal esophagectomy is a safe and effective procedure with good long-term oncological outcomes for locally advanced tumors after neo-adjuvant treatment. It can be recommended for all patients with cancer of the gastroesophageal junction, regardless of the Siewert classification, tumor stage, and comorbidities.

Keywords: Esophageal neoplasms, Neoadjuvant therapy, Esophagectomy, Survival

Introduction

Cancer of the gastroesophageal junction (CGEJ) remains a significant clinical problem with an increasing incidence [1] and is associated with a poor long-term prognosis [2]. Surgical resection remains the mainstay of curative treatment; however, multiple randomized trials have established neoadjuvant treatment as the standard
approach in the management of patients with locally advanced tumors (T3, T4, or node positive) [3, 4]. Consensus on the type of surgery that offers the optimal chance of a cure varies worldwide, especially in relation to the extent of lymphadenectomy. In France, transthoracic esophagectomy (TTE) is recommended for achieving oncological resection with radical en-bloc dissection [5], which could provide a potential long-term survival benefit over transhiatal esophagectomy (THE) [6, 7]. Studies on which this recommendation is based enrolled only patients who did not receive neoadjuvant therapy and showed similar overall 5-year survival rates in both groups (36% vs. 34%) in recently updated results [8, 9].

The main argument in favor of TTE is the supposedly higher number of lymph nodes retrieved than with THE, as a minimum of 23 nodes harvested is currently recommended [7, 9]. Indeed, detractors argue that THE does not allow an optimal lymphadenectomy, unlike the thoracic approach. However, the impact of an extended lymphadenectomy on survival is still debated, because studies on this matter combined adenocarcinoma and squamous cell carcinoma, despite their different tumoral and biologic behavior [10–15], and mixed patients with and without neoadjuvant treatment [7, 10, 16]. Moreover, it appears that the number of lymph nodes examined decreases after neoadjuvant treatment with a modified distribution of metastases, predominating in the abdominal and peritumoral sites [17], with the number resected being equal using the two approaches.

The main advantage of THE is reduced morbidity, especially cardiorespiratory complications.

Consequently, there is no strong evidence to support the use of one technique over the other. The purpose of this study was to report our oncological results with THE for locally advanced CGEJ after neoadjuvant treatment.

**Methods**

**Patient selection**

Between February 2006 and December 2018, 120 consecutive patients with locally advanced CGEJ, according to the Siewert classification [18], underwent surgical resection with curative intent at the Institut Paoli Calmettes (Marseille, France), and their medical records were subsequently reviewed. Patients with metastatic disease or poor general status precluding extensive surgery were excluded. All patient data were entered prospectively into a clinical database, which was approved by both the Institutional Review Board and the ethics committee (N° IPC 2019-057). Informed consent was obtained from all patients before surgery, and the study protocol was conducted in accordance with the 1989 World Medical Association Declaration of Helsinki.

**Preoperative assessment**

Initial and preoperative evaluations included upper gastrointestinal endoscopy with biopsy, endoscopic ultrasonography (EUS), thoracic and abdominal computed tomography (CT), and tumor markers [carbohydrate antigen 19.9 (CA 19-9) and carcinoembryonic antigen (CEA)]. Staging laparoscopy and positron emission tomography (PET) were not routinely performed.

The included patients received neoadjuvant treatment in accordance with previous recommendations [3, 4]. At our institution, we standardized this treatment according to the tumor location; patients received chemotherapy (Siewert II and III) or chemoradiation (CRT) (Siewert I) if the tumor was classified as T3/T4 and/or N+ based on EUS findings. In case of doubt or impossibility of determining the precise location of the lesion at the time of EUS, the choice of treatment was based on CT findings; CRT was indicated when the tumor was mainly located in the thorax, and chemotherapé was indicated when the tumor was mainly located in the abdomen or at the junction.

Perioperative chemotherapy agents evolved throughout the study period and consisted of platinum and fluorouracil in combination with epirubicin [4, 19] or docetaxel [20], according to recommendations and the data in the literature.

Neoadjuvant CRT consisted of a total dose of 45 Gy delivered according to the technique described by Bosset et al. [21] combined with concurrent chemotherapy (platinum-based chemotherapy and 5-FU).

**Surgery**

The same surgeon performed all resections, with the help of a second surgeon during the cervical phase. Surgery was performed through the open bi-subcostal approach or laparoscopically. Patients with Siewert III tumors underwent classical total gastrectomy [5] and were consequently not included in the present study. However, THE was performed when the intrathoracic location of the upper pole of the tumor did not allow for total gastrectomy with gastroesophageal anastomosis (in case of large tumor volume or hiatal hernia). Tissue and lymph nodes along the common hepatic artery, celiac trunk, and top of the pancreas and those from the splenic artery to the spleen were removed en-bloc, along with lymph nodes along the lesser curve of the stomach, cardia, and specimen. A wide splitting of the esophageal hiatus (with an incision in the right diaphragmatic crus) allowed for dissection of the lower mediastinum with circumferential removal of the fat pad around the thoracic esophagus as far as the carina under visual control (the aorta was viewed backward, the mediastinal pleura...
were resected on both sides, and the pericardium was viewed forward, serving as the margins for dissection. After left-sided mobilization and retrosternal dissection of the cervical esophagus and upper mediastinum without lymphadenectomy, blind dissection was not necessary. Gastrointestinal continuity was re-established using a 5- to 10-cm-wide gastric tube that was vascularized by the right gastro-epiploic artery and positioned within the posterior mediastinum via cervical end-to-end anastomosis with manual interrupted stitches (PDS 4.0).

Mediastinal and cervical drains were systematically inserted, but chest tubes were not routinely used. Enteral nutrition was supplied through a feeding jejunostomy from day 1, and the patients were allowed oral feeding after the nasogastric tube was removed between days 3 and 7. A water-soluble oral contrast study was conducted only on the suspicion of dehiscence of the anastomosis.

Histological analysis
All tumors were staged according to the seventh edition of the American Joint Commission on Cancer Staging Manual's (AJCC 7) criteria for esophageal cancer by an experienced pathologist [22]. The surgeon identified all groups of removed lymph nodes intraoperatively and submitted them as separate specimens for counting and examination according to their location. A negative margin (R0) was defined as a clear circumferential and longitudinal margin [22].

Study parameters
Postoperative mortality was defined as death occurring within 90 days after surgery. Postoperative morbidity was graded according to the Clavien-Dindo classification [23].

Delayed complications were defined as any complication that occurred more than 1 month after THE and included principally recurrent laryngeal nerve injury and benign anastomotic stricture.

Patient follow-up
After discharge, patients were routinely followed up at the outpatient hospital at 1 month postoperatively. Considering their recovery status, patients were offered adjuvant therapy based on the same regimen as that for preoperative chemotherapy, regardless of the results of pathological examination. In case of preoperative radiotherapy, no adjuvant treatment was offered. A physical examination, CT, and tumor marker analysis (CA 19.9 and CEA) were performed at 4-month intervals for 2 years and twice a year for 5 years or until death.

Statistical analysis
All statistical analyses were performed at the significance level of $\alpha = 0.05$ using SAS® 9.4 software (SAS Institute, Cary, NC). Categorical variables were summarized as frequencies (%) calculated based on available data and quantitative variables as medians (range). Continuous data were compared using the Mann-Whitney $U$ test and categorical data using the Fisher exact test.

Overall survival (OS) and disease-free survival (DFS) were defined from the date of operation. Patients without events were right-censored at the date of their most recent follow-up. Survival endpoints were estimated using the Kaplan-Meier method. For administrative reasons, the OS and DFS data were censored after 10 years of follow-up.

Multivariate Cox models that included the ASA score, Siewert classification, number of harvested lymph nodes, and pTNM stage as independent covariates were analyzed. The associated hazard ratios (HRs) were estimated with their Wald's bilateral confidence intervals and $p$-values.

Results
Demographic data
Demographic details of the 120 patients are shown in Table 1. More than 90% of the patients had a T3 esophageal adenocarcinoma at diagnosis, with suspected lymph node involvement in 96 patients (80%). Fifty-six patients (46.7%) received preoperative chemotherapy and 64 (53.3%) received preoperative CRT.

Surgery and postoperative course
The intraoperative and postoperative outcomes are listed in Table 2. Two patients (1.6%) required thoracotomy: one to repair a wound of the left main bronchus and one to repair an aortic wound. The overall 90-day morbidity and mortality rates were 56.7% and 0.8%, respectively. One patient had unexplained circulatory collapse during the surgical intervention and died on postoperative day 25 due to toxic shock.

The anastomotic failure rate was 16% ($n = 19$). All patients who developed a fistula had a favorable outcome within 2–4 weeks, with a median oral refeeding time of 14 days (range 7–55 days). However, the occurrence of a fistula significantly prolonged the median length of hospital stay (36.3 vs. 18.6 days, $p < 0.01$).

The overall respiratory complication rate was 31.7% ($n = 38$). The severe respiratory complication rate was 20.8% ($n = 25$), including pleural drainage alone (Clavien-Dindo 3a; $n = 14$) and reintubation for respiratory failure (Clavien-Dindo 4, $n = 11$).

The benign anastomotic stricture rate was significantly higher in patients who experienced a fistula (42.1% vs. 6.9%, $p < 0.01$). All patients with benign strictures were successfully treated by endoscopic dilatation at a median of 3.2 sessions.
Recurrent laryngeal nerve injury occurred in 12 patients (9.9%). The hoarseness was usually transient due to vocal cord paresis and resolved within 2–12 weeks. Eight patients with persistent dysphonia (6.6%) required cord medialization.

### Histopathological analysis

Results of the histopathological analysis of the operative specimens are summarized in Table 3. Curative resection (R0) was achieved in 115 patients (95.8%). Radial margins were involved in 4 patients with T4a or T3N+ tumors on pathological staging. A median of 17.5 lymph nodes were dissected from each specimen, and lymph node metastases were found in 53 patients (44.2%). The most frequent sites of nodal metastases were the celiac axis (n = 36), mediastinum (n = 23), and lesser curvature of the stomach (n = 22), showing no significant difference according to the Siewert classification. The mean lymph node ratio was 0.26 (range 0.04–0.79, median 0.15). In 22 patients (18.3%), there was a complete pathological response to neoadjuvant treatment (16 after CRT and 6 after chemotherapy).

### Survival and recurrence

At a median follow-up of 77.8 months, the overall 1-, 3-, and 5-year survival rates of all patients were 91% (95% confidence interval 84%–95%), 75% (66%–83%), and 65% (54%–74%), respectively (Fig. 1). The median OS time was not reached. Forty-four (36.7%) patients received adjuvant treatment (chemotherapy: 29 patients, CRT: 15 patients).

Forty-nine patients (40.8%) developed recurrent disease in the peritoneum (n = 14), lungs (n = 11), liver (n = 10), lymph nodes (n = 9), and anastomotic site (n = 5). DFS at 3 years was 56% (47–65%) (Fig. 2).

The sites of recurrent lymph nodes were the supraclavicular (n = 3), cervical (n = 1), upper mediastinum (n = 5), and lumboaortic (n = 5) regions. These sites were
associated with metastases in other locations in 50% of cases. There was no correlation between the type of preoperative treatment and site of lymph node recurrence.

Multivariate analyses showed that only TNM stage was independently associated with poor prognosis (Tables 4 and 5). The Siewert classification, ASA score, and number of harvested lymph nodes were not significantly related to OS or DFS.

**Discussion**

Our monocentric series showed that THE was a safe technique and provided good oncologic outcomes in patients with locally advanced CGEJ.

**Postoperative course**

Despite a high morbidity rate (57.1%), we observed a dramatically low mortality rate (1.2%) compared with other esogastric surgical procedures [12, 24–27]. We made the choice to use the Clavien-Dindo classification, as recommended by the esophagectomy complications consensus group [28], considering all complications until postoperative day 90. However, the widely varying definitions for complications used make comparisons between studies difficult. Minor complications are scarcely described in esophageal surgery studies because they are very secondary to life-threatening complications but they represent half of the complications identified in our study.

Patients who experienced anastomotic leakage in our series developed moderate sepsis with isolated cervical suppuration but no mediastinitis. This non-severe event was managed by reopening of the cervical wound and local wound care, and all patients showed favorable outcomes.

The overall respiratory complication rate (31.6%) was higher than that in other studies [7, 14], but only one-third of these complications were major complications. The other two-thirds only required physiotherapy, antibiotics, or short-term pleural drainage, with no major repercussions.

Unlike TTE, we did not perform routine thoracic but only active abdominal drainage placed in the lower mediastinum. However, edema after neoadjuvant CRT, chylothorax, and/or large bilateral mediastinal pleura resection may cause fluid to accumulate into the thorax and indicate postoperative pleural drainage (17.5% in our series).

**Oncologic results**

Tumor stage, surgical resection margin, and lymph node status are the most important predictors of outcome in patients with esophageal cancer [11, 25]. Opponents of THE claim that the performance of a more extended resection to the upper mediastinum improves the latter two criteria, and thus long-term survival [7, 26]. Their conclusions are based on studies that included all esophageal tumors, regardless of their location or pathological features, and in the absence of neoadjuvant treatment.

Some authors suggest that radical TTE reduces the likelihood of margin involvement, particularly in patients with T3 to T4 tumors [6, 26]. Although it is accepted that THE cannot offer the same access to the mediastinum, the lack of standardization in the volume of periesophageal tissue resection [27, 29] is a confounder that undermines studies assessing surgical radicality. Despite the high portion of advanced tumors at diagnosis in our

### Table 3 Pathological findings

| Pathological findings            | Overall cohort, no. (%) |
|----------------------------------|-------------------------|
| **Tumor classification**         |                         |
| pT0-Tis                          | 24 (20%)                |
| pT1                              | 15 (12.5%)              |
| pT2                              | 25 (20.8%)              |
| pT3                              | 53 (44.2%)              |
| pT4                              | 3 (2.5%)                |
| **Tumor size, mm³**              |                         |
|                                  | 30 (0-160)              |
| **Nodes classification**         |                         |
| pN0                              | 67 (55.8%)              |
| pN1                              | 25 (20.8%)              |
| pN2                              | 15 (12.5%)              |
| pN3                              | 13 (10.8%)              |
| **Stage**                        |                         |
| Stage 0                          | 22 (18.3%)              |
| Stage I                          | 13 (10.8%)              |
| Stage II                         | 34 (28.3%)              |
| Stage III                        | 36 (30%)                |
| Stage IV                         | 15 (12.5%)              |
| **Number of examined LN³**       | 17.5 (6-36)             |
| **Number of mediastinal examined LN** | 4 (0-16) |
| **Number of positive lymph nodesa** | 3 (1-23) |
| Perineural invasion              | 22 (18.3%)              |
| Vascular embolism                | 20 (16.7%)              |
| **Tumor differentiation**        |                         |
| Poor                             | 16 (13.3%)              |
| Intermediate                     | 37 (30.8%)              |
| Well                             | 41 (34.2%)              |
| Mucinous                         | 2 (1.7%)                |
| Sterilized tumor                 | 24 (20%)                |
| **Margin status**                |                         |
| R0                               | 115 (95.8%)             |
| R1                               | 5 (4.2%)                |

**LN**: lymph node, **p**: post-therapeutic classification

* Expressed as median (range)
series, the rates of microscopically positive (R1) resection margins (2.5%) and local/locoregional recurrence (4.2%) were low, comparing favorably with previously published results for patients with CGEJ undergoing TTE with curative intent [8, 9, 16, 30–32].

We need to qualify our very favorable results by noting that they not only be attributed to the surgical technique but also to the neoadjuvant therapy administered to all patients with T3–T4 tumors, where tumor reduction likely limited the incomplete local resection risks [30]. Nevertheless, the main controversy remains the optimal extent of lymphadenectomy. A median of 17.5 lymph nodes was examined from each specimen, including mediastinal lymph nodes, exceeding the results of published series of THE [8, 17, 33] and achieving comparable lymphadenectomy than TTE [11, 14, 16, 24]. The only randomized study conducted failed to demonstrate a significant association between the higher lymph node yield in the TTE group and an increased 5-year overall survival rate [9]. Furthermore, in a post hoc analysis of the randomized CROSS-II trial, the total number of resected nodes was only correlated with improved OS after surgery alone, whereas the number of invaded lymph nodes was correlated with survival in both groups [16]. Currently, there is increased consensus that this criterion is a prognostic factor after the resection of adenocarcinoma of the esophagus or esophagogastric junction, as is the case with the lymph node ratio [10, 13, 32, 34]. In our study, just over 50% of patients had evidence of nodal metastases after neoadjuvant therapy, which is significantly less than the clinical N-stage (80%). This finding suggests that tumoral regression occurred at the nodal level after neoadjuvant therapy. Indeed, a study demonstrated that after neoadjuvant therapy, not only did the frequency of lymph node metastases decrease but also there was a change in their distribution [35].

Based on a multivariate analysis of the entire population, the only predictive factor of survival in our study was the tumor stage. The 5-year OS rate of nearly 65% observed in this study is in stark contrast to that
**Table 4** Multivariate analysis of the overall survival

| ASA score | Patients | Events, no. (%) | HR [95% CI] | p    |
|-----------|----------|-----------------|-------------|------|
| 1–2       | 107      | 36 (33.6%)      |             |      |
| 3–4       | 13       | 3 (23.1%)       | 0.87 [0.25–3.02] | 0.82 |

| Siewert classification | Patients | Events, no. (%) | HR [95% CI] | p    |
|------------------------|----------|-----------------|-------------|------|
| Siewert I              | 63       | 24 (38.1%)      |             |      |
| Siewert II–III         | 57       | 15 (26.3%)      | 0.51 [0.25–1.07] | 0.07 |

| TNM stage | Patients | Events, no. (%) | HR [95% CI] | p    |
|-----------|----------|-----------------|-------------|------|
| Stage 1–2 | 69       | 16 (23.2%)      |             |      |
| Stage 3–4 | 51       | 23 (45.1%)      | 3.94 [1.92–8.09] | < 0.001 |

| Number of harvested LNs | Patients | Events, no. (%) | HR [95% CI] | p    |
|------------------------|----------|-----------------|-------------|------|
| < 15                   | 42       | 18 (42.9%)      |             |      |
| ≥ 15                   | 78       | 21 (26.9%)      | 0.6 [0.3–1.2] | 0.15 |

**Table 5** Multivariate analysis of the disease-free survival

| ASA score | Patients | Events, no. (%) | HR [95% CI] | p    |
|-----------|----------|-----------------|-------------|------|
| 1–2       | 107      | 51 (47.7%)      |             |      |
| 3–4       | 13       | 5 (38.5%)       | 0.89 [0.34–2.34] | 0.81 |

| Siewert classification | Patients | Events, no. (%) | HR [95% CI] | p    |
|------------------------|----------|-----------------|-------------|------|
| Siewert I              | 63       | 30 (47.6%)      |             |      |
| Siewert II–III         | 57       | 26 (45.6%)      | 0.75 [0.41–1.37] | 0.35 |

| TNM stage | Patients | Events, no. (%) | HR [95% CI] | p    |
|-----------|----------|-----------------|-------------|------|
| Stage 1–2 | 69       | 23 (33.3%)      |             |      |
| Stage 3–4 | 51       | 33 (64.7%)      | 3.39 [1.88–6.12] | < 0.001 |

| Number of harvested LN | Patients | Events, no. (%) | HR [95% CI] | p    |
|------------------------|----------|-----------------|-------------|------|
| < 15                   | 42       | 22 (52.4%)      |             |      |
| ≥ 15                   | 78       | 34 (43.6%)      | 0.72 [0.39–1.31] | 0.28 |

**HR** hazard ratio, **CI** confidence interval, **p** Wald’s test p value for significance, **LN** lymph node
previously reported [8, 14, 24-26, 32, 33]. Recent studies assessing survival after neoadjuvant treatment and resection for adenocarcinoma of the esophagus reported 3-year OS rates of 53.9–57.4% [30] and 5-year rates of 33–44.3% [31, 36] regardless of the surgical technique. The only study focusing on locally advanced tumors included patients without neoadjuvant treatment and epidermoid tumors. The 5-year survival rates were 35% after TTE and 19% after THE [12].

This highlights the difficulty of comparing our results with those of previous studies due to the heterogeneity in disease stage and preoperative treatment.

While the surgical technique used was standardized and applied uniformly, different neoadjuvant regimens were used during the study period. This problem is inevitable when assessing the long-term survival for this type of pathology [30, 31, 36], as practices have evolved considerably following the publication of multicenter randomized trials [4, 19, 20].

Our study is limited by its monocentric non-comparative design. However, the prospective evaluation, large sample of patients with homogeneous tumor characteristics, and lack of exclusion criteria allow us to propose some relevant points that may add to the debate regarding the optimal therapy for CGEJ.

Conclusions

THE meets the oncological surgical quality criteria both for the extent of resection and quality of lymphadenectomy in locally advanced CGEJ tumors after neoadjuvant treatment. Furthermore, it shows excellent oncological outcomes in terms of survival. This technique can be recommended for all patients with CGEJ, regardless of the tumor stage and patients’ comorbidities.

In the era of neoadjuvant therapy and minimally invasive surgery, oncologic safety after THE remains to be proven in large randomized controlled studies.

Acknowledgements

None.

Authors’ contributions

Conception and design: Hélène Meillat, Christophe Zemmour, Jacques Ewald, and Jérôme Guiramand. Acquisition of data: Hélène Meillat, Vincent Niziers, and Jean-Philippe Ratone. Analysis and interpretation of data: Christophe Zemmour. Drafting of the paper: Hélène Meillat, Vincent Niziers, Jacques Ewald, Slimane Dermeche, and Jérôme Guiramand. Revision of the paper: Christophe Zemmour, Jean-Philippe Ratone, Slimane Dermeche. Final approval: Hélène Meillat, Vincent Niziers, Christophe Zemmour, Jacques Ewald, Jean-Philippe Ratone, Slimane Dermeche, and Jérôme Guiramand. All authors read and approved the final manuscript.

Funding

None declared.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author, [HMM], upon reasonable request.

Declarations

Ethics approval and consent to participate

All patient data were entered prospectively into a clinical database, which was approved by both the Institutional Review Board and the ethics committee (N° IPC 2019-057).

Consent for publication

Informed consent was obtained from all patients before surgery, and the study protocol was conducted in accordance with the 1989 World Medical Association Declaration of Helsinki.

Competing interests

All authors declare that they have no competing interests.

Author details

1 Department of Digestive Surgical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13009 Marseille, France. 2 Department of Clinical Research & Investigation, Biostatistics & Methodology Unit, Paoli Calmettes Institute, Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France. 3 Digestive Endoscopy Unit, Paoli Calmettes Institute, Marseille, France. 4 Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.

Received: 19 November 2021   Accepted: 21 February 2022

Published online: 06 March 2022

References

1. Pennathur A, Gibson MK, Jove BA, et al. Oesophageal carcinoma. Lancet. 2013;381:400–12.
2. Then EO, Lopez M, Saleem S, et al. Esophageal Cancer: an update surveillance epidemiology and end results database analysis. World J Oncol. 2020;11:55–64.
3. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
4. Cunningham D, Allum WH, Stening SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
5. Gronnier C, Piessen G, Mariette C. Diagnosis and treatment of non-metastatic esophagogastric junction adeno carcinoma: what are the current options? J Visc Surg. 2012;149:e23–33.
6. Orringer MB, Marshall B, Chang AC, et al. Two thousand transthiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363–72.
7. Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202:588–96.
8. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transthiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.
9. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transthiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1000.
10. Altorki NK, Zhou X, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.
11. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.
12. Kutup A, Nentwich MF, Bollschweiler E, et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transthiatal esophagectomy. Ann Surg. 2014;260:1016–20.
13. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of
neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.

14. Davies AR, Sandhu H, Pillar A, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101:511–7.

15. Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol. 2020;18:59.

16. Koen Talsma A, Shapiro J, Looman CW, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260:786–92.

17. Hagens ERC, Kunzli HT, van Rijswijk AS, et al. Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study. Surg Endosc. 2019. https://doi.org/10.1007/s00464-019-07205-y.

18. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.

19. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

20. Al-Batran SE, Homann N, Pauli‑Magy A, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro‑oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

21. Bosset JF, Lorchel F, Mantion G, et al. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol. 2005;92:239–45.

22. American Joint Committee on Cancer. Esophagus and Esophagogastric junction. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer Verlag; 2009.

23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

24. Ovrebo KK, Lie SA, Laerum OD, et al. Long‑term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy. World J Surg Oncol. 2012;10:130.

25. Markar SR, Grennier C, Duhamel A, et al. Significance of microscopically incomplete resection margin after esophageal cancer. Ann Surg. 2016;253:712–8.

26. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg. 2001;234:581–7.

27. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for locally advanced, resectable gastric or gastro‑oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

28. Hagens ERC, Kunzli HT, van Rijswijk AS, et al. Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study. Surg Endosc. 2019. https://doi.org/10.1007/s00464-019-07205-y.

29. Pang W, Liu G, Zhang Y, et al. Total laparoscopic transabdominal‑trans‑diaphragmatic approach for treating Siewert II tumors: a prospective analysis of a case series. World J Surg Oncol. 2021;19:26.

30. Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocarcinoma: multi‑center European comparative study. Ann Oncol. 2017;28:519–27.

31. Visser E, Edholm D, Smithers BM, et al. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. J Surg Oncol. 2018;117:1687–96.

32. Xu H, Zhang L, Miao J, Liu S, Liu H, Jia T, et al. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study. World J Surg Oncol. 2020;18:144.

33. Hulscher JB, Tijssen JG, Obertop H, et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta‑analysis. Ann Thorac Surg. 2001;72:306–13.

34. Zhou Z, Zhang H, Xu Z, Li W, Dang C, Song Y. Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction. World J Surg Oncol. 2015;13:197.

35. Castoro C, Scarpa A, Cagol M, et al. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol. 2011;18:3743–54.

36. Davies AR, Myoteri D, Zylstra J, et al. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. Br J Surg. 2018;105:1639–49.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.